Evogene Ltd. and Unravel Biosciences, Inc. entered into a scientific collaboration on January 7 2026 to design and optimize small‑molecule therapeutics that could restore myelin and reverse neurological damage in demyelinating diseases such as multiple sclerosis.
The partnership combines Evogene’s ChemPass AI generative‑chemistry engine with Unravel’s BioNAV™ predictive biology platform and Living Molecular Twins™ patient data. Together the teams will target a novel demyelination pathway identified by Unravel and use ChemPass AI’s multiparameter optimization to accelerate lead discovery and brain‑penetrant molecule design.
The collaboration is a milestone‑driven revenue opportunity for Evogene, which has reported declining revenue in recent quarters—$2.4 million in Q1 2025 and $3.2 million in the first half of 2025—alongside net losses of $3.0 million and $7.7 million, respectively. Evogene’s cash position stood at roughly $16 million as of September 30 2025, underscoring the strategic importance of new partnership revenue streams.
Unravel Biosciences has raised a total of $4.5 million across multiple funding rounds, including a $500 k seed round in 2021. The company’s AI‑driven approach has already translated into clinical‑grade discoveries in rare diseases, positioning it to contribute robust data to the joint program.
Multiple sclerosis affects an estimated 3 million people worldwide. The global MS therapeutic market was valued at $27.85 billion in 2024 and is projected to reach $49.64 billion by 2034, creating a sizable addressable opportunity for a successful remyelination therapy.
Ofer Haviv, Evogene’s President and CEO, said the partnership “leverages Unravel’s success in identifying a druggable target and Evogene’s AI capabilities to design brain‑penetrant molecules, bringing us closer to a transformative treatment for patients with demyelinating diseases.”
While the specific target and preclinical validation timeline remain undisclosed, the collaboration represents a strategic pivot for Evogene toward high‑impact pharmaceutical development and a potential new revenue stream that could offset its recent financial challenges.
The partnership is expected to progress through preclinical validation in the coming years, with milestone payments and royalties to be negotiated as the program advances. The collaboration’s success will hinge on the ability to translate the novel target into a drug‑like molecule that can cross the blood‑brain barrier and promote remyelination.
The announcement signals a significant shift in Evogene’s business model, moving from a broad AI‑driven platform company toward focused therapeutic development in a high‑growth market. The partnership’s potential to generate milestone revenue and position Evogene as a player in the MS space could materially impact its long‑term financial outlook.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.